ADC Therapeutics (NYSE:ADCT – Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.06, Zacks reports. The business had revenue of $19.00 million during the quarter, compared to analyst estimates of $19.01 million.
ADC Therapeutics Trading Down 3.0 %
NYSE:ADCT traded down $0.05 during trading hours on Friday, hitting $1.48. 81,554 shares of the stock traded hands, compared to its average volume of 614,205. The firm has a 50 day moving average price of $1.67 and a 200 day moving average price of $2.27. The firm has a market cap of $142.62 million, a price-to-earnings ratio of -0.62 and a beta of 1.51. ADC Therapeutics has a fifty-two week low of $1.39 and a fifty-two week high of $5.38.
Wall Street Analysts Forecast Growth
Several research firms have issued reports on ADCT. Cantor Fitzgerald restated an “overweight” rating on shares of ADC Therapeutics in a research report on Friday, March 7th. Stephens lifted their target price on ADC Therapeutics from $6.00 to $8.00 and gave the stock an “overweight” rating in a report on Monday, February 24th. Guggenheim reaffirmed a “buy” rating and set a $10.00 target price on shares of ADC Therapeutics in a report on Thursday, December 12th. Finally, HC Wainwright reissued a “buy” rating and issued a $8.00 price target on shares of ADC Therapeutics in a research note on Monday, January 6th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $8.50.
About ADC Therapeutics
ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.
Read More
- Five stocks we like better than ADC Therapeutics
- What Is WallStreetBets and What Stocks Are They Targeting?
- Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback
- Manufacturing Stocks Investing
- JPMorgan: The ‘NVIDIA of Banking’ Poised for More Gains?
- How to Invest in Insurance Companies: A Guide
- Buy the Chewy Stock Reversal? Here’s Why Now Is the Time
Receive News & Ratings for ADC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
